The coronavirus disease 2019 (COVID-19) pandemic case has highlighted their great potential and the chance to create mAbs from bench to bedside in under 6?a few months (Kelley, 2020). R-ABA can be applied on the huge size for the fast id of bactericidal antibodies and had been validated by regular methods. Implementation of the approaches will end up being instrumental towards the advancement of new medicines and vaccines against and various other bacterial pathogens to aid the fight antimicrobial level of resistance. Keywords: monoclonal antibodies, (Kirkcaldy et al., 2019). It really is due to the host-adapted individual pathogen (Quillin and Seifert, 2018), which is certainly listed as a higher concern pathogen for analysis into novel remedies with the Globe Health Firm (WHO) due to its capability to quickly develop level of resistance to antibiotics (Unemo and Shafer, 2011; Prez-Gracia and Suay-Garca, 2018). Recently surfaced gonococcus strains demonstrated level of resistance to most available antibiotics including ceftriaxone which represents the final remaining choice for first-line treatment (Unemo and Shafer, 2014; Unemo et al., 2016). Despite initiatives over many years, no vaccine or particular treatment have however been successfully created to counter-top gonococcal attacks and book strategies have to P4HB be applied to do this objective (Russell et al., 2019). Individual monoclonal antibodies (mAbs) show great potential in the fight infectious diseases, against viral pathogens especially. Indeed, mAbs are really effective and particular toward their goals, and nowadays can be developed faster than any other drug. The coronavirus disease 2019 (COVID-19) pandemic case has highlighted their great potential and the possibility to bring mAbs from bench to bedside in less than 6?months Clafen (Cyclophosphamide) (Kelley, 2020). This milestone was achieved thanks to the unprecedented technological and methodological advancement of the last two decades in the field of B cell analyses and mAb screening. Indeed, this scenario has permitted to interrogate the human antibody repertoire and to quickly screen hundreds of thousands of antibodies to select the optimal candidates for clinical development. Conversely, the field of mAb screening and selection against bacterial pathogens is hampered by the lack of efficient screening assays. The serum bactericidal assay (SBA), conventionally used to evaluate the functional activity of sera or mAbs surrogate assay to evaluate the immunogenicity of bacterial vaccines against cholera (Jang et al., 2016) and meningococcal disease (Balmer and Borrow, 2004), it is not suitable for Clafen (Cyclophosphamide) high-throughput mAb screening. To respond to this unmet need, we herein report the development of two high-throughput (HT) assays named Clafen (Cyclophosphamide) luminescence-based (L-ABA) and resazurin-based (R-ABA) antibody bactericidal assays (Figures 1A,?,B),B), for rapid screening and identification of antibodies against gonococcus and AMR bacteria. Open in a separate window Figure 1 Workflow for monoclonal antibody based high-throughput serum bactericidal assays. (ACC) Schematic representation of the workflows implemented for Clafen (Cyclophosphamide) the L-ABA (A), R-ABA (B), and C-SBA (C). Materials and methods Bacterial strain and preparation strain FA1090 (ATCC 700825), was used in this study. Fresh cultures of bacteria were prepared from frozen stocks by streaking onto gonococcal agar (GCA) consisting of gonococcal (GC) agar base supplemented with 1% v/v IsoVitaleX (BD Biosciences, Franklin Lakes, NJ, United States). On the following day, bacteria were grown in GC liquid medium at 37C, 5% CO2 starting from an optical density at 600 nanometers (OD600) 0.1 until mid-log phase cultures, i.e., OD600 0.5. Source of complement Baby rabbit complement (BRC; Cedarlane) was used as a source of complement for serum sensitivity and for all ABA assays. For optimized ABA assays, BRC was diluted to 10% v/v for use as a complement source, which is within the recommended range of 10C20% v/v for gonococcal bactericidal assays (McQuillen et al., 1994). For negative controls with heat-inactivated complement (hiBRC), BRC was heated at 56C for 1?h. Complement toxicity assay was grown to mid-log phase (OD600?=?0.5) as described above. Bacterial cultures were then directly diluted in sterile Dulbeccos phosphate-buffered saline (DPBS) supplemented with 2% fetal bovine serum (FBS; Hyclone) and 0.1% glucose (from now on named as ABA buffer). To assess the optimal OD600, different dilutions were used. Specifically, starting from cultures at OD600 0.5, bacteria were diluted 1:5, 1:10, and 1:100 to obtain.